NasdaqGS:ANNX 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
31 Mar 24	-121	29	102
31 Dec 23	-134	30	114
30 Sep 23	-141	31	119
30 Jun 23	-143	33	119
31 Mar 23	-145	34	118
31 Dec 22	-142	33	113
30 Sep 22	-145	35	111
30 Jun 22	-145	35	111
31 Mar 22	-140	34	106
31 Dec 21	-130	31	100
30 Sep 21	-116	26	91
30 Jun 21	-103	21	75
31 Mar 21	-84	17	60
31 Dec 20	-70	14	49
30 Sep 20	-56	11	38
30 Jun 20	-45	10	33
31 Mar 20	-42	9	30
31 Dec 19	-38	8	25
30 Sep 19	-34	7	22
30 Jun 19	-28	6	18
31 Mar 19	-23	4	16
31 Dec 18	-18	4	16

質の高い収益: ANNXは現在利益が出ていません。

利益率の向上: ANNXは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ANNXは利益が出ておらず、過去 5 年間で損失は年間28.9%の割合で増加しています。

成長の加速: ANNXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ANNXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: ANNXは現在利益が出ていないため、自己資本利益率 ( -46.01% ) はマイナスです。

Annexon 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Recent updates

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Price target increased by 13% to US$16.40

Annexon, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Annexon, Inc. Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

New major risk - Share price stability

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Annexon, Inc. Presents New Neuro Protection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy

Annexon, Inc., Annual General Meeting, Jun 05, 2024

Annexon: Unforced Error Sullies Prospects

Price target increased by 9.0% to US$15.17

Annexon, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Insider selling

New major risk - Share price stability

Executive VP notifies of intention to sell stock

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125.01642 million.

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125.01642 million.

New major risk - Revenue and earnings growth

Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

New minor risk - Market cap size

Price target increased by 10% to US$15.60

New major risk - Revenue and earnings growth

Price target increased by 9.0% to US$15.33

Annexon, Inc. Appoints Jamie Dananberg as Chief Medical Officer

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Price target decreased by 18% to US$15.43

Annexon, Inc. Announces Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?

Annexon, Inc. Highlights Strategic Focus to Advance Four Complement Programs Through Late-Stage Development and Progress Across Three Therapeutic Franchises

Annexon, Inc. Announces Executive Changes

We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

Price target decreased to US$18.71

Annexon started as a buy at Jefferies on market potential of candidates, data catalysts

Annexon: A First Take

Price target decreased to US$24.25

Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02

Annexon, Inc. announced that it has received $130.475296 million in funding from a group of investors

Annexon, Inc. announced that it expects to receive $130.475296 million in funding from a group of investors

Annexon to raise $130M in stock and warrant offering

Annexon, Inc.(NasdaqGS:ANNX) dropped from Russell 2500 Index

Annexon, Inc. Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’S Disease

Price target decreased to US$30.80

CEO, President & Director recently bought US$147k worth of stock

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Price target decreased to US$30.80

Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy

Price target decreased to US$34.20

Annexon, Inc. Announces Resignation of Sanjay Keswani as Executive Vice President and Chief Medical Officer

Annexon, Inc. Announces Resignation of Ricky Sun as Board Member

Annexon, Inc. Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition

CEO, President & Director exercised options to buy US$1.5m worth of stock.

Executive VP & Chief Scientific Officer Ted Yednock has left the company

Executive VP & Chief Scientific Officer exercised options and sold US$297k worth of stock

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Annexon, Inc Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases

Annexon, Inc.(NasdaqGS:ANNX) dropped from Russell 2500 Growth Index

Executive VP & CFO exercised options and sold US$52k worth of stock

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Annexon, Inc. Announces Executive Changes

Independent Director has left the company

New 90-day high: US$33.04

Independent Director has left the company

Independent Chairman William Young has left the company

Annexon, Inc. Announces Executive Changes

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

New 90-day low: US$22.00

New 90-day high: US$30.55

Annexon, Inc. Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome

Dosing underway in Annexon's Phase 2/3 study of monoclonal antibody in Guillain-Barré Syndrome

Annexon Biosciences EPS misses by $0.43

Annexon, Inc. Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntington’s Disease Clinical Program

収支内訳

収益と収入の歴史

過去基準チェック /06